<- Back to digest

JBJS - 2026-10-07 - Journal Article; Review

Harnessing the Biologic Power of Bacteriophages to Improve the Treatment of Periprosthetic Joint Infection: Barriers and Future Directions.

Abdelbary H, Malko S, Taha M, Crawley AM, Powell JN, Abedi AA, Suh GA, Citak M

systematic reviewLOE Vn = N/AN/A

Topics

arthroplasty
PMID: 42520109DOI: 10.2106/JBJS.26.00339View on PubMed ->

Key Takeaway

Bacteriophage therapy shows preclinical promise as a PJI adjuvant but faces regulatory, pharmacokinetic, and resistance barriers that prevent integration into standard care, where current 2-stage revision failure rates reach 10–30%.

Summary Depth

Choose how much analysis to show on this article page.

Summary

This expert review, informed by the 2025 Istanbul International Consensus Meeting, synthesizes the therapeutic rationale and clinical barriers for bacteriophage therapy as an adjuvant in PJI management. Phages offer biofilm-penetrating, bacteria-specific lytic activity that conventional antibiotics cannot replicate against established biofilm. Key barriers identified include narrow host range requiring patient-specific phage selection, phage resistance emergence, lack of standardized pharmacokinetic data in the periprosthetic environment, and absence of regulatory frameworks for phage-antibiotic combination protocols.

Key Limitation

No clinical outcome data are presented; all therapeutic claims rest on preclinical evidence, making translation to patient-level decision-making premature.

Original Abstract

➢ Periprosthetic joint infection (PJI) remains the most common cause of failure after total joint arthroplasty, with current standard therapies associated with failure rates between 10% and 30%. ➢ The 2025 International Consensus Meeting in Istanbul, Türkiye, highlighted the potential benefits of bacteriophage (phage) therapy in managing PJI. ➢ One of the barriers to integrating phage therapy into standard clinical PJI care is the knowledge gap between preclinical research and clinical practice. ➢ This Expert Review summarizes the key therapeutic advantages of using phages as an adjuvant therapeutic platform for PJI. It also highlights the current challenges that are continuing to limit the integration of phages into standard PJI care.